Lixte Biotechnology Holdings Past Earnings Performance
Past criteria checks 0/6
Lixte Biotechnology Holdings's earnings have been declining at an average annual rate of -11.9%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-11.9%
Earnings growth rate
-0.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -292.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 08
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
May 05Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Jan 20We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
Jul 20Lixte Biotechnology starts enrollment in early-stage lung cancer study
Jun 02Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?
Feb 25Revenue & Expenses Breakdown
How Lixte Biotechnology Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -4 | 3 | 1 |
| 30 Jun 24 | 0 | -4 | 3 | 1 |
| 31 Mar 24 | 0 | -5 | 4 | 1 |
| 31 Dec 23 | 0 | -5 | 4 | 1 |
| 30 Sep 23 | 0 | -6 | 4 | 1 |
| 30 Jun 23 | 0 | -6 | 5 | 1 |
| 31 Mar 23 | 0 | -6 | 5 | 1 |
| 31 Dec 22 | 0 | -6 | 5 | 1 |
| 30 Sep 22 | 0 | -7 | 5 | 2 |
| 30 Jun 22 | 0 | -6 | 5 | 2 |
| 31 Mar 22 | 0 | -7 | 5 | 2 |
| 31 Dec 21 | 0 | -7 | 5 | 2 |
| 30 Sep 21 | 0 | -6 | 4 | 1 |
| 30 Jun 21 | 0 | -6 | 4 | 2 |
| 31 Mar 21 | 0 | -5 | 3 | 2 |
| 31 Dec 20 | 0 | -3 | 2 | 1 |
| 30 Sep 20 | 0 | -3 | 2 | 1 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 0 | -2 | 2 | 1 |
| 31 Dec 19 | 0 | -2 | 2 | 1 |
| 30 Sep 19 | 0 | -2 | 2 | 1 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 2 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
| 30 Sep 18 | 0 | -2 | 2 | 0 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
| 31 Mar 18 | 0 | -2 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 1 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -2 | 2 | 1 |
| 31 Dec 16 | 0 | -2 | 1 | 1 |
| 30 Sep 16 | 0 | -2 | 1 | 1 |
| 30 Jun 16 | 0 | -2 | 1 | 2 |
| 31 Mar 16 | 0 | -2 | 1 | 2 |
| 31 Dec 15 | 0 | -3 | 1 | 2 |
| 30 Sep 15 | 0 | -3 | 1 | 2 |
| 30 Jun 15 | 0 | -3 | 1 | 1 |
| 31 Mar 15 | 0 | -3 | 1 | 1 |
| 31 Dec 14 | 0 | -3 | 1 | 1 |
| 30 Sep 14 | 0 | -3 | 1 | 1 |
| 30 Jun 14 | 0 | -2 | 1 | 1 |
| 31 Mar 14 | 0 | -2 | 1 | 1 |
Quality Earnings: LIXT is currently unprofitable.
Growing Profit Margin: LIXT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LIXT is unprofitable, and losses have increased over the past 5 years at a rate of 11.9% per year.
Accelerating Growth: Unable to compare LIXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LIXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LIXT has a negative Return on Equity (-292.66%), as it is currently unprofitable.